Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Variable mannose-binding lectin expression during postoperative acute-phase response.

J W Olivier Van Till1, Marja A Boermeester, Piet W Modderman

  • 1Department of Surgery, Academic Medical Center Amsterdam, University of Amsterdam, The Netherlands.

Surgical Infections
|November 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.

The Lancet. Oncology·2026
Same author

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT-OES-1 Trial.

International journal of cancer·2026
Same author

Active surveillance for esophageal cancer after clinically complete response: relevant considerations of the SANO-trial.

Journal of thoracic disease·2026
Same author

Pathological Outcomes After Uncertain Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer.

Annals of surgery·2026
Same author

Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements.

The British journal of surgery·2026
Same author

Health-related quality of life of patients undergoing active surveillance versus standard surgery for oesophageal cancer (SANO trial).

The British journal of surgery·2026

Low mannose-binding lectin (MBL) levels predict MBL expression during acute-phase responses. A baseline plasma MBL concentration of 0.5 µg/mL effectively identifies MBL gene variants, aiding in preoperative risk assessment for infections.

Area of Science:

  • Immunology
  • Genetics
  • Surgical Medicine

Background:

  • Low mannose-binding lectin (MBL) concentrations and genetic variations are linked to infectious complications.
  • MBL deficiency's role during surgery-induced acute-phase responses requires further investigation.

Purpose of the Study:

  • To investigate MBL expression and deficiency during an acute-phase response following surgery.
  • To determine if baseline MBL levels predict MBL expression post-surgery.
  • To assess the utility of a specific MBL plasma concentration cutoff for identifying MBL gene variants.

Main Methods:

  • Collected blood samples from 20 patients undergoing abdominal surgery (transhiatal esophagectomy) at multiple time points.
  • Measured plasma concentrations of MBL, C-reactive protein (CRP), and secretory phospholipase A2 (sPLA2).

Related Experiment Videos

  • Classified patients based on preoperative MBL levels (<0.5 or ≥0.5 µg/mL) and confirmed MBL deficiency via genetic sequencing.

    • Main Results:

    • Baseline MBL concentrations strongly correlated with maximal postoperative MBL levels (r = 0.88, p < 0.0001).
    • No significant correlation was observed between baseline and maximal concentrations for CRP or sPLA2.
    • Genetic variants in MBL alleles were found in 40% of patients, associated with lower MBL levels (p = 0.005).
    • A baseline MBL cutoff of 0.5 µg/mL demonstrated 100% sensitivity and 83% specificity in identifying exon-1 MBL variants.

    Conclusions:

    • Preoperative plasma MBL concentration is a reliable predictor of MBL expression during the acute-phase response.
    • A baseline MBL cutoff of 0.5 µg/mL can identify patients with MBL exon-1 variants without genetic sequencing.
    • This simple method allows for preoperative identification of MBL-deficient patients at risk for infectious complications.